Ortho-R is being studied in rotator cuff tear repair. OrthoRTI plans to enroll 78 patients for its phase 1 and 2 clinical trials in the fall.
The trial was put on hold in June, and OrthoRTI submitted data related to the drug’s chemistry, manufacturing and control to the FDA in July.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.